TPST1

Across TCGA pan-cancer cohorts, TPST1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TPST1 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher TPST1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TPST1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

GBM, LUAD, and PDAC are the cancer types where TPST1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.421	0.666	.003	13	view →
LUAD	DFS	Quartile	All	0.856	0.350	<.001	10	view →
PDAC	OS	Quartile	II,III,IV	0.567	0.354	.017	4	view →
HNSC	DFS	Median	II,III,IV	0.975	0.911	.046	2	view →
LSCC	DFS	Median	All	0.905	1.000	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TPST1–GBM (OS)

Open the GBM breakdown →